The Effectiveness and Tolerability of Aripiprazole for Pediatric Bipolar Disorders: A Retrospective Chart Review

• DOI: 10.1089/cap.2004.14.593
• Publication Date: 2005-01-20T11:12:43Z
• Authors: Drew H. Barzman; Melissa P. DelBello; Robert A. Kowatch; Beth Gernert; David E. Fleck; Sanjeev Pathak; Katherine Rappaport; Sergio V. Delgado; Pamela Campbell; Stephen M. Strako...
• Keywords: Aripiprazole; Tolerability; Clinical Global Impression; Bipolar I disorder

The aim of this retrospective chart review was to evaluate the effectiveness and tolerability aripiprazole for treatment children adolescents with bipolar disorders.The medical charts all a DSM-IV diagnosis disorder, type I, II, not otherwise specified (NOS), or schizoaffective type, who were treated reviewed by two child adolescent psychiatrists independently confirmed their diagnoses, severity, improvement illness using Clinical Global Impression (CGI) Severity Improvement scores disorder (CGI-BP) Assessment Scale (CGAS).Thirty patients identified (mean starting dose=9 +/- 4 mg/day, mean final dose=10 3 mg/day). overall response rate, defined CGI-Improvement score < = 2 at endpoint, 67%. There statistically significant in CGAS (48 11 65 11, signed rank 191, p <0.0001) CGI-S (4.2 0.8 2.8 1.0, rank=-172, <0.0001, effect size=1.90) from baseline endpoint. No serious adverse events identified. Common side effects sedation (n=10, 33%), akathisia (n=7, 23%), gastrointestinal disturbances (n=2, 7%). Baseline endpoint weights available 14 (47%) patients. Change weight ranged +5 -21 kg 12 (86%) lost loss 6 kg).This suggests that may be effective well tolerated disorders. Controlled studies pediatric are necessary.